0857 GMT - Swiss pharma giant Roche's lymphoma drug Columvi getting EU approval as a second-line treatment is positive but expected, Vontobel analyst Stefan Schneider says in a note. Columvi is the first treatment for patients with relapsed or refractory diffuse B-cell lymphoma in Europe who didn't respond to initial treatment. Shares rise 2.5% to 250 Swiss francs.(helena.smolak@wsj.com)
(END) Dow Jones Newswires
April 14, 2025 04:57 ET (08:57 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.